Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology

Authors:
Al B. Benson III Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Al B. Benson III in
Current site
Google Scholar
PubMed Close
 MD
,
Alan P. Venook UCSF Helen Diller Family Comprehensive Cancer Center;

Search for other papers by Alan P. Venook in
Current site
Google Scholar
PubMed Close
 MD
,
Mahmoud M. Al-Hawary University of Michigan Rogel Cancer Center;

Search for other papers by Mahmoud M. Al-Hawary in
Current site
Google Scholar
PubMed Close
 MD
,
Mustafa A. Arain UCSF Helen Diller Family Comprehensive Cancer Center;

Search for other papers by Mustafa A. Arain in
Current site
Google Scholar
PubMed Close
 MD
,
Yi-Jen Chen City of Hope National Medical Center;

Search for other papers by Yi-Jen Chen in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Kristen K. Ciombor Vanderbilt-Ingram Cancer Center;

Search for other papers by Kristen K. Ciombor in
Current site
Google Scholar
PubMed Close
 MD
,
Stacey A. Cohen Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

Search for other papers by Stacey A. Cohen in
Current site
Google Scholar
PubMed Close
 MD
,
Harry S. Cooper Fox Chase Cancer Center;

Search for other papers by Harry S. Cooper in
Current site
Google Scholar
PubMed Close
 MD
,
Dustin A. Deming University of Wisconsin Carbone Cancer Center;

Search for other papers by Dustin A. Deming in
Current site
Google Scholar
PubMed Close
 MD
,
Ignacio Garrido-Laguna Huntsman Cancer Institute at the University of Utah;

Search for other papers by Ignacio Garrido-Laguna in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Jean L. Grem Fred & Pamela Buffett Cancer Center;

Search for other papers by Jean L. Grem in
Current site
Google Scholar
PubMed Close
 MD
,
Sarah E. Hoffe Moffitt Cancer Center;

Search for other papers by Sarah E. Hoffe in
Current site
Google Scholar
PubMed Close
 MD
,
Joleen Hubbard Mayo Clinic Cancer Center;

Search for other papers by Joleen Hubbard in
Current site
Google Scholar
PubMed Close
 MD
,
Steven Hunt Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Steven Hunt in
Current site
Google Scholar
PubMed Close
 MD
,
Ahmed Kamel O'Neal Comprehensive Cancer Center at UAB;

Search for other papers by Ahmed Kamel in
Current site
Google Scholar
PubMed Close
 MD
,
Natalie Kirilcuk Stanford Cancer Institute;

Search for other papers by Natalie Kirilcuk in
Current site
Google Scholar
PubMed Close
 MD
,
Smitha Krishnamurthi Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

Search for other papers by Smitha Krishnamurthi in
Current site
Google Scholar
PubMed Close
 MD
,
Wells A. Messersmith University of Colorado Cancer Center;

Search for other papers by Wells A. Messersmith in
Current site
Google Scholar
PubMed Close
 MD
,
Jeffrey Meyerhardt Dana-Farber/Brigham and Women’s Cancer Center;

Search for other papers by Jeffrey Meyerhardt in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Eric D. Miller The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

Search for other papers by Eric D. Miller in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Mary F. Mulcahy Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Mary F. Mulcahy in
Current site
Google Scholar
PubMed Close
 MD
,
Steven Nurkin Roswell Park Comprehensive Cancer Center;

Search for other papers by Steven Nurkin in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Michael J. Overman The University of Texas MD Anderson Cancer Center;

Search for other papers by Michael J. Overman in
Current site
Google Scholar
PubMed Close
 MD
,
Aparna Parikh Massachusetts General Hospital Cancer Center;

Search for other papers by Aparna Parikh in
Current site
Google Scholar
PubMed Close
 MD
,
Hitendra Patel UC San Diego Moores Cancer Center;

Search for other papers by Hitendra Patel in
Current site
Google Scholar
PubMed Close
 MD
,
Katrina S. Pedersen Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Katrina S. Pedersen in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Leonard B. Saltz Memorial Sloan Kettering Cancer Center;

Search for other papers by Leonard B. Saltz in
Current site
Google Scholar
PubMed Close
 MD
,
Charles Schneider Abramson Cancer Center at the University of Pennsylvania;

Search for other papers by Charles Schneider in
Current site
Google Scholar
PubMed Close
 MD
,
David Shibata The University of Tennessee Health Science Center;

Search for other papers by David Shibata in
Current site
Google Scholar
PubMed Close
 MD
,
John M. Skibber The University of Texas MD Anderson Cancer Center;

Search for other papers by John M. Skibber in
Current site
Google Scholar
PubMed Close
 MD
,
Constantinos T. Sofocleous Memorial Sloan Kettering Cancer Center;

Search for other papers by Constantinos T. Sofocleous in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Elena M. Stoffel University of Michigan Rogel Cancer Center;

Search for other papers by Elena M. Stoffel in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Eden Stotsky-Himelfarb The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Eden Stotsky-Himelfarb in
Current site
Google Scholar
PubMed Close
 BSN, RN
,
Christopher G. Willett Duke Cancer Institute; and

Search for other papers by Christopher G. Willett in
Current site
Google Scholar
PubMed Close
 MD
,
Alyse Johnson-Chilla National Comprehensive Cancer Network

Search for other papers by Alyse Johnson-Chilla in
Current site
Google Scholar
PubMed Close
 MS
,
Kristina M. Gregory National Comprehensive Cancer Network

Search for other papers by Kristina M. Gregory in
Current site
Google Scholar
PubMed Close
 RN, MSN, OCN
, and
Lisa A. Gurski National Comprehensive Cancer Network

Search for other papers by Lisa A. Gurski in
Current site
Google Scholar
PubMed Close
 PhD
Volume/Issue:
Volume 17: Issue 9
Online Publication Date:
Sep 2019
DOI:
https://doi.org/10.6004/jnccn.2019.0043
Restricted access

Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described.

Individual Disclosures for the NCCN Small Bowel Adenocarcinoma Panel

TU1

  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.

  • 2.

    Noone AM, Howlader N, Krapcho M, et al.. SEER Cancer Statistics Review, 1975-2015, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. National Cancer Institute, Bethesda, MD. 2018. Available at https://seer.cancer.gov/csr/1975_2015/. Accessed August 2, 2019.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Saif MW, editor. Small Bowel Adenocarcinoma. In: Gastrointestinal Malignancies. New York, NY: Demos Medical Publishing, LLC; 2010:171.

  • 4.

    Bilimoria KY, Bentrem DJ, Wayne JD, et al.. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009;249:63–71.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Locher C, Batumona B, Afchain P, et al..Thésaurus National de Cancérologie Digestive (TNCD). Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 2018;50:15–19.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Amin MB, Edge SB, Greene F, et al., editors. AJCC Cancer Staging Manual, 8th Ed. New York: Springer International Publishing; 2017. https://doi.org/10.1007/978-3-319-40618-3

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    U.S. National Library of Medicine-Key MEDLINE® Indicators. Available at: http://www.nlm.nih.gov/bsd/bsd_key.html. Accessed Octboer 8, 2018.

    • PubMed
    • Export Citation
  • 8.

    Bennett CM, Coleman HG, Veal PG, et al.. Lifestyle factors and small intestine adenocarcinoma risk: a systematic review and meta-analysis. Cancer Epidemiol 2015;39:265–273.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Boffetta P, Hazelton WD, Chen Y, et al.. Body mass, tobacco smoking, alcohol drinking and risk of cancer of the small intestine--a pooled analysis of over 500,000 subjects in the Asia Cohort Consortium. Ann Oncol 2012;23:1894–1898.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Algaba A, Guerra I, Marín-Jiménez I, et al.. Incidence, management, and course of cancer in patients with inflammatory bowel disease. J Crohn’s Colitis 2015;9:326–333.

  • 11.

    Cahill C, Gordon PH, Petrucci A, et al.. Small bowel adenocarcinoma and Crohn’s disease: any further ahead than 50 years ago? World J Gastroenterol 2014;20:11486–11495.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Grolleau C, Pote NM, Guedj NS, et al.. Small bowel adenocarcinoma complicating Crohn’s disease: a single-centre experience emphasizing the importance of screening for dysplasia. Virchows Arch 2017;471:611–617.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Laukoetter MG, Mennigen R, Hannig CM, et al.. Intestinal cancer risk in Crohn’s disease: a meta-analysis. J Gastrointest Surg 2011;15:576–583.

  • 14.

    Rampertab SD, Forde KA, Green PH. Small bowel neoplasia in coeliac disease. Gut 2003;52:1211–1214.

  • 15.

    Benhammane H, El M’rabet FZ, Idrissi Serhouchni K, et al.. Small bowel adenocarcinoma complicating coeliac disease: a report of three cases and the literature review. Case Rep Oncol Med 2012;2012:935183.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Zullo A, De Francesco V, Manta R, et al.. A challenging diagnosis of jejunal adenocarcinoma in a celiac patient: case report and systematic review of the literature. J Gastrointestin Liver Dis 2017;26:411–415.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006;101:385–398.

  • 18.

    Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009;4:22.

  • 19.

    Shenoy S. Genetic risks and familial associations of small bowel carcinoma. World J Gastrointest Oncol 2016;8:509–519.

  • 20.

    Tomlinson IP, Houlston RS. Peutz-Jeghers syndrome. J Med Genet 1997;34:1007–1011.

  • 21.

    Hemminki A, Markie D, Tomlinson I, et al.. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184–187.

  • 22.

    Jenne DE, Reimann H, Nezu J, et al.. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38–43.

  • 23.

    Lim W, Hearle N, Shah B, et al.. Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer 2003;89:308–313.

  • 24.

    Giardiello FM, Brensinger JD, Tersmette AC, et al.. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447–1453.

  • 25.

    Hearle N, Schumacher V, Menko FH, et al.. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006;12:3209–3215.

  • 26.

    Koornstra JJ, Kleibeuker JH, Vasen HF. Small-bowel cancer in Lynch syndrome: is it time for surveillance? Lancet Oncol 2008;9:901–905.

  • 27.

    Vasen HF, Wijnen JT, Menko FH, et al.. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020–1027.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Hendriks YM, de Jong AE, Morreau H, et al.. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 2006;56:213–225.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Beamer LC, Grant ML, Espenschied CR, et al.. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 2012;30:1058–1063.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Burt RW. Who should have genetic testing for the Lynch syndrome? Ann Intern Med 2011;155:127–128.

  • 31.

    Matloff J, Lucas A, Polydorides AD, et al.. Molecular tumor testing for Lynch syndrome in patients with colorectal cancer. J Natl Compr Canc Netw 2013;11:1380–1385.

  • 32.

    Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J Clin Oncol 2013;31:2554–2562.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Aparicio T, Svrcek M, Zaanan A, et al.. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer 2013;109:3057–3066.

  • 34.

    Schrock AB, Devoe CE, McWilliams R, et al.. Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol 2017;3:1546–1553.

  • 35.

    Dabaja BS, Suki D, Pro B, et al.. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004;101:518–526.

  • 36.

    Halfdanarson TR, McWilliams RR, Donohue JH, et al.. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 2010;199:797–803.

  • 37.

    Howe JR, Karnell LH, Menck HR, et al.. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer 1999;86:2693–2706.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Overman MJ, Hu CY, Kopetz S, et al.. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol 2012;19:1439–1445.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Negoi I, Paun S, Hostiuc S, et al.. Most small bowel cancers are revealed by a complication. Einstein (Sao Paulo) 2015;13:500–505.

  • 40.

    Gustafsson BI, Siddique L, Chan A, et al.. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy. Int J Oncol 2008;33:1121–1131.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Hara AK, Leighton JA, Sharma VK, et al.. Imaging of small bowel disease: comparison of capsule endoscopy, standard endoscopy, barium examination, and CT. Radiographics 2005;25:697–711., discussion 711–718.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Nylund K, Ødegaard S, Hausken T, et al.. Sonography of the small intestine. World J Gastroenterol 2009;15:1319–1330.

  • 43.

    Chen WG, Shan GD, Zhang H, et al.. Double-balloon enteroscopy in small bowel diseases: eight years single-center experience in China. Medicine (Baltimore) 2016;95:e5104.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Cazzato IA, Cammarota G, Nista EC, et al.. Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. Dig Liver Dis 2007;39:483–487.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Mitsui K, Tanaka S, Yamamoto H, et al.. Role of double-balloon endoscopy in the diagnosis of small-bowel tumors: the first Japanese multicenter study. Gastrointest Endosc 2009;70:498–504.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Sunada K, Yamamoto H, Kita H, et al.. Clinical outcomes of enteroscopy using the double-balloon method for strictures of the small intestine. World J Gastroenterol 2005;11:1087–1089.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Cobrin GM, Pittman RH, Lewis BS. Increased diagnostic yield of small bowel tumors with capsule endoscopy. Cancer 2006;107:22–27.

  • 48.

    Bailey AA, Debinski HS, Appleyard MN, et al.. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol 2006;101:2237–2243.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Cheung DY, Lee IS, Chang DK, et al.. Capsule endoscopy in small bowel tumors: a multicenter Korean study. J Gastroenterol Hepatol 2010;25:1079–1086.

  • 50.

    Boudiaf M, Jaff A, Soyer P, et al.. Small-bowel diseases: prospective evaluation of multi-detector row helical CT enteroclysis in 107 consecutive patients. Radiology 2004;233:338–344.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Soyer P, Aout M, Hoeffel C, et al.. Helical CT-enteroclysis in the detection of small-bowel tumours: a meta-analysis. Eur Radiol 2013;23:388–399.

  • 52.

    Cronin CG, Lohan DG, Browne AM, et al.. Magnetic resonance enterography in the evaluation of the small bowel. Semin Roentgenol 2009;44:237–243.

  • 53.

    Masselli G, Casciani E, Polettini E, et al.. Magnetic resonance imaging of small bowel neoplasms. Cancer Imaging 2013;13:92–99.

  • 54.

    Masselli G, Di Tola M, Casciani E, et al.. Diagnosis of small-bowel diseases: prospective comparison of multi-detector row CT enterography with MR enterography. Radiology 2016;279:420–431.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Cronin CG, Scott J, Kambadakone A, et al.. Utility of positron emission tomography/CT in the evaluation of small bowel pathology. Br J Radiol 2012;85:1211–1221.

  • 56.

    Sakae H, Kanzaki H, Nasu J, et al.. The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study. Br J Cancer 2017;117:1607–1613.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Young JI, Mongoue-Tchokote S, Wieghard N, et al.. Treatment and survival of small-bowel adenocarcinoma in the United States: a comparison with colon cancer. Dis Colon Rectum 2016;59:306–315.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Overman MJ, Hu CY, Wolff RA, et al.. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 2010;116:5374–5382.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Tran TB, Qadan M, Dua MM, et al.. Prognostic relevance of lymph node ratio and total lymph node count for small bowel adenocarcinoma. Surgery 2015;158:486–493.

  • 60.

    Wilhelm A, Müller SA, Steffen T, et al.. Patients with adenocarcinoma of the small intestine with 9 or more regional lymph nodes retrieved have a higher rate of positive lymph nodes and improved survival. J Gastrointest Surg 2016;20:401–410.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Wu S, Chen JN, Zhang QW, et al.. A new metastatic lymph node classification-based survival predicting model in patients with small bowel adenocarcinoma: A derivation and validation study. EBioMedicine 2018;32:134–141.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Zhang S, Yuan W, Zhang J, et al.. Clinicopathological features, surgical treatments, and survival outcomes of patients with small bowel adenocarcinoma. Medicine (Baltimore) 2017;96:e7713.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Hashimoto D, Arima K, Chikamoto A, et al.. Limited resection of the duodenum for nonampullary duodenal tumors, with review of the literature. Am Surg 2016;82:1126–1132.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Onkendi EO, Boostrom SY, Sarr MG, et al.. 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas. J Gastrointest Surg 2012;16:682–691.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Cloyd JM, Norton JA, Visser BC, et al.. Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases. Ann Surg Oncol 2015;22:573–580.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Raghav K, Overman MJ. Small bowel adenocarcinomas--existing evidence and evolving paradigms. Nat Rev Clin Oncol 2013;10:534–544.

  • 67.

    U.S. National Library of Medicine. Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma (BALLAD). ClinicalTrials.gov: 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02502370. Accessed January 9, 2019.

    • PubMed
    • Export Citation
  • 68.

    Evans TRJ, Aparicio T, Malicot KL, et al.. GLOBAL BALLAD: an International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002). [abstract] J Clin Oncol 2016;34(15_suppl):TPS4154–TPS4154.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Ecker BL, McMillan MT, Datta J, et al.. Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: a propensity score-matched analysis. Cancer 2016;122:693–701.

  • 70.

    Swartz MJ, Hughes MA, Frassica DA, et al.. Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. Arch Surg 2007;142:285–288.

  • 71.

    Kelsey CR, Nelson JW, Willett CG, et al.. Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;69:1436–1441.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Aydin D, Sendur MA, Kefeli U, et al.. Evaluation of prognostic factors and adjuvant chemotherapy in patients with small bowel adenocarcinoma who underwent curative resection. Clin Colorectal Cancer 2017;16:220–227.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Ye X, Zhang G, Chen H, et al.. Meta-analysis of postoperative adjuvant therapy for small bowel adenocarcinoma. PLoS One 2018;13:e0200204.

  • 74.

    Kim K, Chie EK, Jang JY, et al.. Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience. Am J Clin Oncol 2012;35:533–536.

  • 75.

    Overman MJ, Kopetz S, Lin E, et al.. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine? Acta Oncol 2010;49:474–479.

  • 76.

    Ecker BL, McMillan MT, Datta J, et al.. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: a propensity score-matched analysis of a nationwide clinical oncology database. Cancer 2017;123:967–976.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449–2460.

  • 78.

    Kim GP, Colangelo LH, Wieand HS, et al.. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007;25:767–772.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Klingbiel D, Saridaki Z, Roth AD, et al.. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol 2015;26:126–132.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Ribic CM, Sargent DJ, Moore MJ, et al.. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247–257.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Sargent DJ, Marsoni S, Monges G, et al.. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219–3226.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Kim JE, Hong YS, Kim HJ, et al.. Defective mismatch repair status was not associated with DFS and OS in stage II colon cancer treated with adjuvant chemotherapy. Ann Surg Oncol 2015; 22(S3, Suppl 3)S630–S637.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Hutchins G, Southward K, Handley K, et al.. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29:1261–1270.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Bertagnolli MM, Redston M, Compton CC, et al.. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 2011;29:3153–3162.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Compton CC, Fielding LP, Burgart LJ, et al.. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979–994.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Fujita S, Shimoda T, Yoshimura K, et al.. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol 2003;84:127–131.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Liebig C, Ayala G, Wilks J, et al.. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 2009;27:5131–5137.

  • 88.

    Grothey A, Sobrero AF, Shields AF, et al.. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378:1177–1188.

  • 89.

    Onkendi EO, Boostrom SY, Sarr MG, et al.. Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy. J Gastrointest Surg 2012;16:320–324.

  • 90.

    Yeung RS, Weese JL, Hoffman JP, et al.. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer 1993;72:2124–2133.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Coia L, Hoffman J, Scher R, et al.. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 1994;30:161–167.

  • 92.

    Minardi AJ, Jr., Zibari GB, Aultman DF, et al.. Small-bowel tumors. J Am Coll Surg 1998;186:664–668.

  • 93.

    Ciresi DL, Scholten DJ. The continuing clinical dilemma of primary tumors of the small intestine. Am Surg 1995;61:698–702., discussion 702–703.

  • 94.

    Ojha A, Zacherl J, Scheuba C, et al.. Primary small bowel malignancies: single-center results of three decades. J Clin Gastroenterol 2000;30:289–293.

  • 95.

    Oh SY, Edwards A, Mandelson M, et al.. Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: comparison of pancreatic cancer and nonpancreatic cancer. Gastrointest Endosc 2015;82:460–8.e2.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    van den Berg MW, Haijtink S, Fockens P, et al.. First data on the Evolution duodenal stent for palliation of malignant gastric outlet obstruction (DUOLUTION study): a prospective multicenter study. Endoscopy 2013;45:174–181.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Upchurch E, Ragusa M, Cirocchi R. Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction. Cochrane Database Syst Rev 2018;5:CD012506.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Facts CS. Small Intestine Cancer. 2019. Available at: https://seer.cancer.gov/statfacts/html/smint.html. Accessed August 7, 2019.

  • 99.

    Adam R, Chiche L, Aloia T, et al..; Association Française de Chirurgie. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006;244:524–535.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Rompteaux P, Gagnière J, Gornet JM, et al.. Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. Eur J Surg Oncol 2019;45:331–335.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Rovers KP, de Bree E, Yonemura Y, et al.. Treatment of peritoneal metastases from small bowel adenocarcinoma. Int J Hyperthermia 2017;33:571–578.

  • 102.

    Legué LM, Simkens GA, Creemers GM, et al.. Synchronous peritoneal metastases of small bowel adenocarcinoma: Insights into an underexposed clinical phenomenon. Eur J Cancer 2017;87:84–91.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Elias D, Glehen O, Pocard M, et al.. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 2010;251:896–901.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Liu Y, Ishibashi H, Takeshita K, et al.. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from small bowel malignancy: results from a single specialized center. Ann Surg Oncol 2016;23:1625–1631.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Liu Y, Yonemura Y, Levine EA, et al.. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal metastases from a small bowel adenocarcinoma: multi-institutional experience. Ann Surg Oncol 2018;25:1184–1192.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Saxena A, Valle SJ, Liauw W, et al.. Recurrence and survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for small bowel adenocarcinoma. Anticancer Res 2017;37:5737–5742.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    van Oudheusden TR, Lemmens VE, Braam HJ, et al.. Peritoneal metastases from small bowel cancer: results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands. Surgery 2015;157:1023–1027.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Quenet F, Elias D, Roca L, et al.. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7 [abstract]. J Clin Oncol 2018;36(suppl): Abstract LBA3503.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol) 2007;19:143–149.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Jigyasu D, Bedikian AY, Stroehlein JR. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer 1984;53:23–25.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Zhang L, Wang LY, Deng YM, et al.. Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China. J BUON 2011;16:689–696.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Aydin D, Sendur MA, Kefeli U, et al.. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO). J BUON 2016;21:1242–1249.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Pedersen K, Smyrk TC, Harrington S, et al.. Programmed death-ligand 1 (PD-L1) expression in small bowel adenocarcinomas (SBA) [abstract]. J Clin Oncol 2015;33(15_suppl):3619.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Thota R, Gonzalez RS, Berlin J, et al.. Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma? Am J Clin Pathol 2017;148:208–214.

  • 115.

    Laforest A, Aparicio T, Zaanan A, et al.. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Eur J Cancer 2014;50:1740–1746.

  • 116.

    Takayoshi K, Kusaba H, Uenomachi M, et al.. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol 2017;80:333–342.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Gulhati P, Raghav K, Shroff R, et al.. Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of Vater. Oncologist 2018;23:277–e26.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Overman MJ, Varadhachary GR, Kopetz S, et al.. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009;27:2598–2603.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Xiang XJ, Liu YW, Zhang L, et al.. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs 2012;23:561–566.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Horimatsu T, Nakayama N, Moriwaki T, et al.. A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. Int J Clin Oncol 2017;22:905–912.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Gibson MK, Holcroft CA, Kvols LK, et al.. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 2005;10:132–137.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Tsushima T, Taguri M, Honma Y, et al.. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist 2012;17:1163–1170.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Zaanan A, Costes L, Gauthier M, et al.. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 2010;21:1786–1793.

  • 124.

    McWilliams RR, Foster NR, Mahoney MR, et al.. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 2017;123:3494–3501.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Gulhati P, Raghav K, Shroff RT, et al.. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of Vater: a single-center, open-label, phase 2 study. Cancer 2017;123:1011–1017.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 126.

    Aydin D, Sendur MA, Kefeli U, et al.. Evaluation of bevacizumab in advanced small bowel adenocarcinoma. Clin Colorectal Cancer 2017;16:78–83.

  • 127.

    Le DT, Uram JN, Wang H, et al.. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–2520.

  • 128.

    U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. 2017. Available at: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm. Accessed January 8, 2019.

    • PubMed
    • Export Citation
  • 129.

    Pedersen K, Foster N, Overman M, et al.. ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA) [abstract]. Ann Oncol 2019;30(Suppl): Abstract # O-007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Overman MJ, McDermott R, Leach JL, et al.. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182–1191.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Overman MJ, Lonardi S, Wong KYM, et al.. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36:773–779.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Overman MJ, Adam L, Raghav K, et al.. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 2018;29:139–144.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Aldrich JD, Raghav KPS, Varadhachary GR, et al.. Retrospective analysis of taxane-based therapy in small bowel adenocarcinoma. Oncologist 2018.

  • 134.

    Zaanan A, Gauthier M, Malka D, et al.. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer 2011;117:1422–1428.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Drilon A, Laetsch TW, Kummar S, et al.. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.

  • 136.

    U.S. Food and Drug Administration. FDA approves larotrectinib for solid tumors with NTRK gene fusions. 2018. Available at: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626720.htm. Accessed November 30, 2018.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Kim M, Jang HJ. The role of small bowel endoscopy in small bowel Crohn’s disease: when and how? Intest Res 2016;14:211–217.

  • 138.

    Simon M, Cosnes J, Gornet JM, et al..GETAID group. Endoscopic detection of small bowel dysplasia and adenocarcinoma in Crohn’s disease: A prospective cohort-study in high-risk patients. J Crohn’s Colitis 2017;11:47–52.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Goverde A, Korsse SE, Wagner A, et al.. Small-bowel surveillance in patients with Peutz-Jeghers syndrome: comparing magnetic resonance enteroclysis and double balloon enteroscopy. J Clin Gastroenterol 2017;51:e27–e33.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Haanstra JF, Al-Toma A, Dekker E, et al.. Prevalence of small-bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy. Gut 2015;64:1578–1583.

  • 141.

    Katsinelos P, Kountouras J, Chatzimavroudis G, et al.. Wireless capsule endoscopy in detecting small-intestinal polyps in familial adenomatous polyposis. World J Gastroenterol 2009;15:6075–6079.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Koornstra JJ. Small bowel endoscopy in familial adenomatous polyposis and Lynch syndrome. Best Pract Res Clin Gastroenterol 2012;26:359–368.

  • 143.

    Postgate A, Hyer W, Phillips R, et al.. Feasibility of video capsule endoscopy in the management of children with Peutz-Jeghers syndrome: a blinded comparison with barium enterography for the detection of small bowel polyps. J Pediatr Gastroenterol Nutr 2009;49:417–423.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Serrano M, Mão-de-Ferro S, Pinho R, et al.. Double-balloon enteroscopy in the management of patients with Peutz-Jeghers syndrome: a retrospective cohort multicenter study. Rev Esp Enferm Dig 2013;105:594–599.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    van Lier MG, Wagner A, Mathus-Vliegen EM, et al.. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010;105:1258–1264., author reply 1265.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Drini M, Speer A, Dow C, et al.. Management of duodenal adenomatosis in FAP: single centre experience. Fam Cancer 2012;11:167–173.

  • 147.

    Hewitt M, Greenfield S, and Stovall E, (eds). From Cancer Patient to Cancer Survivor: Lost in Transition. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council. Washington, DC: National Academy of Sciences; 2006. Available at http://www.nap.edu/catalog/11468.html

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Jansen L, Herrmann A, Stegmaier C, et al.. Health-related quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study. J Clin Oncol 2011;29:3263–3269.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Lynch BM, Steginga SK, Hawkes AL, et al.. Describing and predicting psychological distress after colorectal cancer. Cancer 2008;112:1363–1370.

  • 150.

    Mols F, Beijers T, Lemmens V, et al.. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013;31:2699–2707.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 151.

    Thong MS, Mols F, Wang XS, et al.. Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry. Eur J Cancer 2013;49:1957–1966.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Wright P, Downing A, Morris EJ, et al.. Identifying social distress: a cross-sectional survey of social outcomes 12 to 36 months after colorectal cancer diagnosis. J Clin Oncol 2015;33:3423–3430.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Denlinger CS, Barsevick AM. The challenges of colorectal cancer survivorship. J Natl Compr Canc Netw 2009;7:883–894.

Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
25
Article Category:
Research Article
Print Publication Date:
01 Sep 2019
Online Publication Date:
Sep 2019

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 32651 7556 1700
PDF Downloads 16886 2162 116
EPUB Downloads 0 0 0